Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use

Eur Respir J. 2017 Jul 27;50(1):1700311. doi: 10.1183/13993003.00311-2017. Print 2017 Jul.

Abstract

Early data from the CU programme show delamanid may be effective in MDR/XDR-TB with few treatment options http://ow.ly/tA6Y30cs2Yg

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents / pharmacology*
  • Child
  • Communicable Disease Control
  • Compassionate Use Trials
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Female
  • Global Health
  • Humans
  • Male
  • Middle Aged
  • Nitroimidazoles / pharmacology*
  • Oxazoles / pharmacology*
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • World Health Organization

Substances

  • Antitubercular Agents
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles